[Genetic polymorphism of oxidative drug metabolism. Therapeutic and toxicologic implications].
D000319:Adrenergic beta-Antagonists / Q000378:metabolism; D003577:Cytochrome P-450 Enzyme System / Q000235:genetics; D003647:Debrisoquin / Q000009:adverse effects / Q000378:metabolism; D006801:Humans; D006900:Hydroxylation; D008617:Mephenytoin / Q000378:metabolism; D010084:Oxidation-Reduction; D010480:Perhexiline / Q000378:metabolism; D004364:Pharmaceutical Preparations / Q000378:metabolism*; D010615:Phenacetin / Q000378:metabolism; D010629:Phenformin / Q000378:metabolism; D010641:Phenotype; D010672:Phenytoin / Q000378:metabolism; D011110:Polymorphism, Genetic; D011955:Receptors, Drug / Q000235:genetics; D013034:Sparteine / Q000009:adverse effects / Q000378:metabolism
D000319:Adrenergic beta-Antagonists; D004364:Pharmaceutical Preparations; D011955:Receptors, Drug; D013034:Sparteine; D010672:Phenytoin; D003577:Cytochrome P-450 Enzyme System; D010629:Phenformin; D010615:Phenacetin; D010480:Perhexiline; D008617:Mephenytoin; D003647:Debrisoquin
Genetische Polymorphismen des oxidativen Arzneimittelstoffwechsels. Therapeutische und toxikologische Implikationen.